Bone marrow transplantation (BMT)) has become a steady part of treatment for an increasing number of children and young adults with either malignant or non malignant hematologic disorders. The preparative regimens used before BMT include high-dose chemotherapy, with or without total body irradiation (TBI). Since both modalities affect normal as well as abnormal cells, the conditioning regimens are associated with early and late side effects (1-8). In allogeneic BMT further causes of toxicity can be related to graft versus host disease and immunosuppressive therapy following BMT. A knowledge of early and late toxicities is the basis for an exact cost-benefit evaluation and for a correct informed consensus before starting a BMT program. Over the past 10 years, an increasing effort has been made to study early and late effects in children receiving allogeneic BMT. Less information is available about children receiving autologous BMT (ABMT). The aim of this paper is to report the protocol of endocrine evaluation of children receiving allogeneic or autologous BMT and the preliminar results of growth assessment of children alive disease free, through March 31st 1991.
|Number of pages||3|
|Journal||Bone Marrow Transplantation|
|Issue number||SUPPL. 1|
|Publication status||Published - 1991|
ASJC Scopus subject areas